头孢氨苄的体外抗菌活性和人类药理学,一个新的口服吸收头孢菌素C的抗生素。

文章的细节

引用

复制到剪贴板

Thornhill TS,奥尔特我,约翰逊WD,凯D

头孢氨苄的体外抗菌活性和人类药理学,一个新的口服吸收头孢菌素C的抗生素。

:Microbiol。1969年3月,17 (3):457 - 61。

PubMed ID

4388601 (在PubMed

]

文摘

浓度头孢氨苄(一种口服吸收的导数头孢菌素C)在血清和尿液测定正常志愿者和病人。体外抗菌活性也进行了研究。所有菌株A组beta-hemolytic链球菌和肺炎双球菌被3.1杯/毫升。金黄色葡萄球菌菌株的,88%是被6.3杯/ ml,和12.5杯/毫升抑制金黄色葡萄球菌,大肠杆菌的80%,72%的Klebsiella-Aerobacter,变形杆菌菌株的56%。大约90 - 96%的大肠杆菌,克雷伯氏菌气杆菌,p .君子兰菌株被25个杯子每毫升。假单胞菌和头孢氨苄indole-positive变形杆菌菌株被证明是相当耐头孢氨苄。头孢氨苄口服后吸收良好。头孢氨苄的血清浓度峰值至少5杯/毫升每个志愿者也取得了250和500毫克剂量。平均血清浓度的峰值7.7杯/毫升和250毫克剂量达到;12.3杯/毫升达到了500毫克剂量的抗生素。食物没有干扰的吸收。 Probenecid enhanced both the peak serum concentration and the duration of antibiotic activity in the serum. Over 90% of the administered dose was excreted in the urine within 6 hr. The mean peak serum concentration of cephalexin after an oral dose of 500 mg was adequate to inhibit all group A streptococci, D. pneumoniae, and S. aureus, 85% of E. coli, and about 40 to 75% of Klebsiella-Aerobacter and P. mirabilis strains. Levels of cephalexin in urine were adequate to inhibit over 90% of E. coli, and P. mirabilis and 80 to 96% of Klebsiella-Aerobacter strains.

DrugBank数据引用了这篇文章

药物

头孢氨苄